The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple, literature-backed premise: negative headline shocks tend to be overreacted to and revert toward fundamentals. It buys names hit by sentiment below -0.4 that are already oversold — RSI14 under 35 and trading below their SMA20 — and sizes into the panic. It exits on reversion (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The design cites recent q-fin work on sentiment feedback and retail heterogeneity (arXiv:2509.11970, 2025), corroborated by stock-level investor-sentiment research. The universe is 24 mega-cap and large-cap names across tech, financials, healthcare, staples, and energy — a deliberately liquid, well-covered set where sentiment data is dense and slippage is low.
Validation performance
This is where PanicFade v4 earns attention. Across a 4-fold walk-forward test spanning September 2021 to August 2026, all four folds were positive — 1.6%, 3.88%, 10.14%, and 21.7% — with returns notably improving over time rather than decaying. The most recent fold posted a 2.44 Sharpe against a shallow 2.6% max drawdown. Aggregate deflated statistics are encouraging: a Probabilistic Sharpe Ratio of 0.985 and a Deflated Sharpe Ratio of 0.56 across 27 trials, which is a meaningful guard against the overfitting that plagues backtested strategies.
The full backtest returned 37.93% over 1,233 days (6.79% CAGR) with a 62.88% win rate over 530 trades, a Sharpe of 0.96, and a 9.3% max drawdown. The reviewer approved it at risk 0.35, flagging only minor sizing and assumption caveats.
The strengths
Monotonically improving folds are rare and hard to fake — this isn't a strategy propped up by one lucky regime. The shallow drawdowns (never above 9.3% in any fold) and a win rate near 63% suggest the reversion edge is real and the risk controls are working. The deflated statistics surviving 27 trials is the single most reassuring number here.
The risks
Two things temper the enthusiasm. First, a 6.79% CAGR and a full-sample Sharpe under 1.0 are modest — the headline 37.93% is spread thin over three-plus years, and much of the strength is concentrated in the final fold. A single strong regime doing heavy lifting is always worth watching. Second, and more immediately: since going live on August 6, PanicFade v4 has executed zero trades. Four scheduled runs (Aug 6, 7, 10 and the deploy) all returned 0 executed, 0 rejected, with cash flat at $10,000.
That silence is by design — the entry conditions are strict, and a calm, grinding-higher tape simply won't trigger a fade. But it also means the live track record is, so far, entirely theoretical. The backtest's 5,807% turnover implies this strategy is meant to be active; its current dormancy is a reminder that a panic-fade needs panic to fade.
Bottom line
PanicFade v4 is one of the more rigorously validated strategies we've deployed — genuinely convincing on paper. The open question is entirely about live execution: it is now waiting, patiently and correctly, for a market shock it can lean into. Until one arrives, the jury stays out.